Terns Pharmaceuticals, Inc. (NASDAQ: TERN)

Terns Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics for oncology and metabolic disorders. Its primary focus is oncology, with the lead asset TERN 701, an oral allosteric BCR ABL1 inhibitor designed for the treatment of chronic myeloid leukemia, currently advancing through Phase 1/2 clinical trials. The company also maintains a discovery pipeline for additional undisclosed oncology targets and retains legacy metabolic programs, including TERN 501, a thyroid hormone receptor β agonist for metabolic dysfunction associated steatohepatitis and obesity, and TERN 801, a glucose dependent insulinotropic polypeptide receptor antagonist aimed at obesity. These metabolic assets are being pursued through strategic partnerships. Terns Pharmaceuticals emphasizes internal innovation, having discovered all of its pipeline candidates internally, and aims to bring first in class or best in class therapies to patients with high unmet medical need.

As a pre revenue entity, Terns Pharmaceuticals generates income principally through licensing and collaboration agreements. The company has an existing arrangement with Jiangsu Hansoh Pharmaceutical Group for TERN 701 in Greater China, which includes an upfront payment of $0.8 million, potential milestone payments worth up to $67 million contingent on clinical, regulatory and sales achievements, and tiered royalties on net sales. Similar partnership models are being sought for the TERN 501 and TERN 801 programs to fund further development. No product sales have been recorded to date.

Within the competitive landscape of chronic myeloid leukemia therapeutics, Terns Pharmaceuticals contends with established pharmaceutical giants such as Novartis, Bristol Myers Squibb, Pfizer and Takeda, as well as specialized biotechnology firms including Ascentage Pharma Group, Innovent Biologics, Enliven Therapeutics and Incyte Corporation. The company's differentiation lies in its internally discovered allosteric inhibitor TERN 701, which targets the BCR ABL1 myristoyl pocket and offers a once daily oral regimen without food restrictions, potentially improving efficacy, safety and tolerability compared with existing agents like asciminib. Additionally, TERN 701 has received orphan drug designation and fast track status from the U. S. Food and Drug Administration, underscoring its therapeutic promise and providing regulatory advantages that may accelerate development and market entry. The disease affects approximately ninety six thousand five hundred individuals annually in the United States, with a prevalence exceeding seventy five thousand cases, representing a significant unmet need for improved therapies. Terns Pharmaceuticals believes that its candidate could capture a meaningful share of this market by offering a differentiated mechanism and a convenient dosing schedule.

The company's customers are primarily pharmaceutical and biotechnology partners with whom it engages in licensing, co development and commercialization arrangements. A concrete example is the collaboration with Jiangsu Hansoh Pharmaceutical Group, which holds exclusive rights to develop and commercialize TERN 701 in Greater China. Terns Pharmaceuticals is also actively seeking strategic allies to advance its metabolic programs TERN 501 and TERN 801, indicating that its customer base consists of firms capable of providing funding, expertise and market access for early stage assets. In addition, the company works with academic institutions and contract research organizations to support preclinical and clinical studies, further expanding its network of collaborators.